{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T00:53:25Z","timestamp":1794531205276,"version":"4.9.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NTNU Norwegian University of Science and Technology"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>In the sustainable development goals (SDG) context of seeking universal health coverage, the expanding gap between the supply of specialized and primary health-care providers of headache-related health care and the care needs of the very large number of people affected by headache is a formidable but not insoluble public-health challenge.<\/jats:p>\n          <jats:p> Structured headache services provide a cost-effective framework wherein controlled patient flows enable the care needs of people with headache to be met at appropriate levels, but these services may still be overwhelmed by inappropriate demand.<\/jats:p>\n          <jats:p>Community pharmacists are an underutilized resource, potentially well able to provide the solution. To do so, they must, as a profession, be integrated into structured headache services.<\/jats:p>\n          <jats:p>What remains to be determined is how to achieve this integration in an encouraging climate for change, which recognises the potential for relieving strained health-care systems and meeting a range of health-care needs by expanding pharmacists\u2019 scope of practice.<\/jats:p>\n          <jats:p>This position statement on behalf of the European Headache Federation (EHF) and <jats:italic>Lifting The Burden<\/jats:italic> (LTB) is formally endorsed by the International Pharmaceutical Federation (FIP).<\/jats:p>","DOI":"10.1186\/s10194-025-02021-3","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T06:09:05Z","timestamp":1746511745000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The role of community pharmacists in managing common headache disorders, and their integration within structured headache services: position statement on behalf of the European Headache Federation (EHF) and Lifting The Burden (LTB: the Global Campaign against Headache), with the formal endorsement of the International Pharmaceutical Federation"],"prefix":"10.1186","volume":"26","author":[{"given":"Heba","family":"BaniHani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Lampl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoinette","family":"MaassenvandenBrink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal Mohammad","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise Ninett","family":"Carlsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Coppola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Deligianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Gil-Gouveia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip R.","family":"Holland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas K.","family":"Hus\u00f8y","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rigmor","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madalena","family":"Pl\u00e1cido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Reuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Ryli\u0161kien\u0117","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarita","family":"Sanchez del R\u00edo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik Winther","family":"Schytz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erling","family":"Tronvik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Versijpt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"Steiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,6]]},"reference":[{"key":"2021_CR1","unstructured":"World Health Organization Sustainable development goals (SDG) Target 3.8 | Achieve universal health coverage (UHC). https:\/\/www.who.int\/data\/gho\/data\/major-themes\/universal-health-coverage-major. Accessed 23 Jan 2025"},{"key":"2021_CR2","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1016\/S0140-6736(24)00757-8","volume":"403","author":"AJ Ferrari","year":"2023","unstructured":"Ferrari AJ, Santomauro DF, Aali A et al (2023) Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 403:2133\u20132161. https:\/\/doi.org\/10.1016\/S0140-6736(24)00757-8","journal-title":"Lancet"},{"key":"2021_CR3","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41582-022-00763-1","volume":"19","author":"TJ Steiner","year":"2023","unstructured":"Steiner TJ, Stovner LJ (2023) Global epidemiology of migraine and its implications for public health and health policy. Nat Rev Neurol 19:109\u2013117. https:\/\/doi.org\/10.1038\/s41582-022-00763-1","journal-title":"Nat Rev Neurol"},{"key":"2021_CR4","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1111\/j.1468-1331.2011.03612.x","volume":"19","author":"M Linde","year":"2012","unstructured":"Linde M, Gustavsson A, Stovner LJ et al (2012) The cost of headache disorders in Europe: the Eurolight project. Eur J Neurol 19:703\u2013711. https:\/\/doi.org\/10.1111\/j.1468-1331.2011.03612.x","journal-title":"Eur J Neurol"},{"key":"2021_CR5","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s10194-021-01265-z","volume":"22","author":"TJ Steiner","year":"2021","unstructured":"Steiner TJ, Jensen R, Katsarava Z et al (2021) Structured headache services as the solution to the ill-health burden of headache: 1. Rationale and description. J Headache Pain 22:78. https:\/\/doi.org\/10.1186\/s10194-021-01265-z","journal-title":"J Headache Pain"},{"key":"2021_CR6","unstructured":"World Health Organization, Lifting The Burden (2011) Atlas of headache disorders and resources in the world 2011. https:\/\/www.l-t-b.org\/assets\/4\/E4CCDB33-E96D-B2DE-F4349BBFE1F39655_document\/WHO_LTB_Atlas_of_Headache_Disorders.pdf. Accessed 23 Jan 2025"},{"key":"2021_CR7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41572-022-00415-0","volume":"9","author":"S Ashina","year":"2023","unstructured":"Ashina S, Terwindt G, Steiner T et al (2023) Medication overuse headache. Nature Rev Dis Primer 9:5","journal-title":"Nature Rev Dis Primer"},{"key":"2021_CR8","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s10194-021-01310-x","volume":"22","author":"M Tinelli","year":"2021","unstructured":"Tinelli M, Leonardi M, Paemeleire K et al (2021) Structured headache services as the solution to the ill-health burden of headache. 2. Modelling effectiveness and cost-effectiveness of implementation in Europe: methodology. J Headache Pain 22:99","journal-title":"J Headache Pain"},{"key":"2021_CR9","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s10194-021-01305-8","volume":"22","author":"M Tinelli","year":"2021","unstructured":"Tinelli M, Leonardi M, Paemeleire K et al (2021) Structured headache services as the solution to the ill-health burden of headache. 3. Modelling effectiveness and cost-effectiveness of implementation in Europe: findings and conclusions. J Headache Pain 22:90","journal-title":"J Headache Pain"},{"key":"2021_CR10","unstructured":"European Headache Federation. https:\/\/www.ehf-headache.org. Accessed 23 Jan 2025"},{"key":"2021_CR11","unstructured":"Norwegian Centre for Headache Research \u2013 NorHead. https:\/\/www.ntnu.edu\/norhead. Accessed 23 Jan 2025"},{"key":"2021_CR12","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s10194-022-01420-0","volume":"23","author":"TJ Steiner","year":"2022","unstructured":"Steiner TJ, Birbeck GL, Jensen RH et al (2022) The Global Campaign turns 18: a brief review of its activities and achievements. J Headache Pain 23:49. https:\/\/doi.org\/10.1186\/s10194-022-01420-0","journal-title":"J Headache Pain"},{"key":"2021_CR13","unstructured":"International Pharmaceutical Federation 100+ years of advancing pharmacy worldwide. https:\/\/www.fip.org. Accessed 23 Jan 2025"},{"key":"2021_CR14","unstructured":"UK National Health Executive Over 10,000 pharmacies take part in major NHS primary care expansion. https:\/\/www.nationalhealthexecutive.com\/articles\/over-10000-pharmacies-take-part-major-nhs-primary-care-expansion. Accessed 23 Jan 2025"},{"key":"2021_CR15","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1503\/cmaj.121990","volume":"185","author":"C Tannenbaum","year":"2013","unstructured":"Tannenbaum C, Tsuyuki RT (2013) The expanding scope of pharmacists\u2019 practice: implications for physicians. CMAJ 185:1228\u20131232. https:\/\/doi.org\/10.1503\/cmaj.121990","journal-title":"CMAJ"},{"key":"2021_CR16","unstructured":"Deloitte The future of pharmacy. Disruption creates transformative opportunities and challenges. https:\/\/www2.deloitte.com\/us\/en\/pages\/life-sciences-and-health-care\/articles\/future-of-pharmacy-disruption-opportunities-challenges.html. Accessed 23 Jan 2025"},{"key":"2021_CR17","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.5688\/aj7410s7","volume":"74","author":"PG Manolakis","year":"2010","unstructured":"Manolakis PG, Skelton JB (2010) Pharmacists\u2019 contributions to primary care in the United States collaborating to address unmet patient care needs: the emerging role for pharmacists to address the shortage of primary care providers. Am J Pharm Educ 74:S7. https:\/\/doi.org\/10.5688\/aj7410s7. PMID: 21436916; PMCID: PMC3058447","journal-title":"Am J Pharm Educ"},{"key":"2021_CR18","unstructured":"Deloitte The pharmacist of the future. Unlocking the profession\u2019s potential to improve patient care. https:\/\/www.deloitte.com\/global\/en\/our-thinking\/insights\/industry\/health-care\/future-of-pharmacists.html. Accessed 23 Jan 2025"},{"key":"2021_CR19","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s40267-020-00810-2","volume":"37","author":"N Patel","year":"2021","unstructured":"Patel N, Barnhart R, Konkol P et al (2021) Treatment of migraine: a review of disease burden and an update on the therapeutic landscape for pharmacists. Drugs Ther Perspect 37:100. https:\/\/doi.org\/10.1007\/s40267-020-00810-2","journal-title":"Drugs Ther Perspect"},{"key":"2021_CR20","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s10194-018-0899-2","volume":"20","author":"TJ Steiner","year":"2019","unstructured":"Steiner TJ, Jensen R, Katsarava Z et al (2019) Aids to management of headache disorders in primary care (2nd edition). J Headache Pain 20:57","journal-title":"J Headache Pain"},{"key":"2021_CR21","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1046\/j.1468-2982.1994.1406463.x","volume":"14","author":"TJ Steiner","year":"1994","unstructured":"Steiner TJ, Catarci T, Hering R et al (1994) If migraine prophylaxis does not work, think about compliance. Cephalalgia 14:463\u2013464","journal-title":"Cephalalgia"},{"key":"2021_CR22","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1046\/j.1468-2982.1998.1801052.x","volume":"18","author":"WM Mulleners","year":"1998","unstructured":"Mulleners WM, Whitmarsh TE, Steiner TJ (1998) Noncompliance may render migraine prophylaxis useless, but once-daily regimens are better. Cephalalgia 18:52\u201356","journal-title":"Cephalalgia"},{"key":"2021_CR23","doi-asserted-by":"publisher","first-page":"200317","DOI":"10.5888\/pcd17.200317","volume":"17","author":"MA Strand","year":"2020","unstructured":"Strand MA, Bratberg J, Eukel H et al (2020) Community pharmacists\u2019 contributions to disease management during the COVID-19 pandemic. Prev Chronic Dis 17:200317. https:\/\/doi.org\/10.5888\/pcd17.200317. [Erratum appears in Prev Chronic Dis 2020; 17. http:\/\/www.cdc.gov\/pcd\/issues\/2020\/20_0317e.htm.]","journal-title":"Prev Chronic Dis"},{"key":"2021_CR24","unstructured":"World Health Organization (2023) WHO Model List of Essential Medicines - 23rd list. https:\/\/www.who.int\/publications\/i\/item\/WHO-MHP-HPS-EML-2023.02. Accessed 23 Jan 2025"},{"key":"2021_CR25","doi-asserted-by":"publisher","unstructured":"Kirthi V, Derry S, Moore RA (2013) Aspirin with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev (4):CD008041. https:\/\/doi.org\/10.1002\/14651858.CD008041.pub3","DOI":"10.1002\/14651858.CD008041.pub3"},{"key":"2021_CR26","doi-asserted-by":"publisher","unstructured":"Derry S, Moore RA (2013) Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev (4):CD008040. https:\/\/doi.org\/10.1002\/14651858.CD008040.pub3","DOI":"10.1002\/14651858.CD008040.pub3"},{"key":"2021_CR27","doi-asserted-by":"publisher","unstructured":"Derry CJ, Derry S, Moore RA (2012) Sumatriptan (oral route of administration) for acute migraine attacks in adults. Cochrane Database Syst Rev (2):CD008615. https:\/\/doi.org\/10.1002\/14651858.CD008615.pub2","DOI":"10.1002\/14651858.CD008615.pub2"},{"key":"2021_CR28","doi-asserted-by":"publisher","unstructured":"Moore RA, Wiffen PJ, Derry S et al (2015) Non\u2010prescription (OTC) oral analgesics for acute pain \u2013 an overview of Cochrane reviews. Cochrane Database Syst Rev (11):CD010794. https:\/\/doi.org\/10.1002\/14651858.CD010794.pub2","DOI":"10.1002\/14651858.CD010794.pub2"},{"key":"2021_CR29","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3390\/pharmacy11050155","volume":"11","author":"F Alzahrani","year":"2023","unstructured":"Alzahrani F, Alahmadi YM, Thagfan SSA, Alolayan S, Elbadawy HM (2023) Migraine management in community pharmacies: knowledge, attitude and practice patterns of pharmacists in Saudi Arabia. Pharmacy 11:155. https:\/\/doi.org\/10.3390\/pharmacy11050155. Acessed 23 Jan 2025","journal-title":"Pharmacy"},{"key":"2021_CR30","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/j.1526-4610.2005.05010.x","volume":"45","author":"RG Wenzel","year":"2005","unstructured":"Wenzel RG, Lipton RB, Diamond ML, Cady R (2005) Migraine therapy: a survey of pharmacists\u2019 knowledge, attitudes, and practice patterns. Headache 45:47\u201352. https:\/\/doi.org\/10.1111\/j.1526-4610.2005.05010.x","journal-title":"Headache"},{"key":"2021_CR31","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3390\/pharmacy10040089","volume":"10","author":"G Stavrou","year":"2022","unstructured":"Stavrou G, Siskou OC, Talias MA, Galanis P (2022) Assessing job satisfaction and stress among pharmacists in Cyprus. Pharmacy (Basel, Switzerland) 10:89. https:\/\/doi.org\/10.3390\/pharmacy10040089","journal-title":"Pharmacy (Basel, Switzerland)"},{"key":"2021_CR32","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1097\/AJP.0000000000000063","volume":"30","author":"MA Hadi","year":"2014","unstructured":"Hadi MA, Alldred DP, Briggs M et al (2014) Effectiveness of pharmacist-led medication review in chronic pain management: systematic review and meta-analysis. Clin J Pain 30:1006\u20131014","journal-title":"Clin J Pain"},{"key":"2021_CR33","unstructured":"Rushing S, Burmeister MA (2023) Pharmacy-led pain management in the ED. US Pharm 48:HS8-HS12"}],"updated-by":[{"DOI":"10.1186\/s10194-025-02073-5","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T00:00:00Z","timestamp":1750032000000}}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-025-02021-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-025-02021-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-025-02021-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T07:06:54Z","timestamp":1750057614000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-025-02021-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,6]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2021"],"URL":"https:\/\/doi.org\/10.1186\/s10194-025-02021-3","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s10194-025-02073-5","asserted-by":"object"}]},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,6]]},"assertion":[{"value":"20 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s10194-025-02073-5","URL":"https:\/\/doi.org\/10.1186\/s10194-025-02073-5","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"N\/A.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HBH declares no competing interest. CL has received consulting fees and honoraria for lectures and\/or presentations from AbbVie\/Allergan, Eli Lilly, Lundbeck, Novartis, Pfizer, and Teva, has participated in clinical trials as Eli Lilly\u2019s principal investigator, is associate editor for The Journal of Headache and Pain, and immediate past president and current board member of the European Headache Federation. AMvdB has received personal fees as advisor and speaker from Allergan\/AbbVie, Eli Lilly, Novartis, and Teva, has received research support from Manistee, Novartis, Pfizer, Satsuma and Tonix, declares independent research support from the Dutch Research Council and the Netherlands Organisation for Health Research and Development, is associate editor for The Journal of Headache and Pain, and current president of the European Headache Federation. FMA has received honoraria for lecturing and\/or participating in advisory board meetings for AbbVie, Eli Lilly, Lundbeck, Novartis, Pfizer and Teva, is associate editor for Acta Scandinavica Neurologica, Frontiers in Neurology and Frontiers in Pain Research, is president of the Danish Headache Center and current board member of the European Headache Federation. LNC declares no competing interest. GC is associate editor of The Journal of Headache and Pain, Cephalalgia, Cephalalgia Reports, Frontiers in Neurology (Neurotechnology section) and Frontiers in Human Neuroscience (Brain Imaging and Stimulation section), and current board member of the European Headache Federation. CD has received honoraria and\/or travel grants from Pfizer, Merck, Teva, AstraZeneca, Lundbeck, Teva and Orion Pharma, and is a current board member of the European Headache Federation. RGG has received personal fees for advisory board participation, speaker engagements and involvement in clinical trials from AbbVie, Amgen, Bayer, Eli Lilly, Grunenthal, Lundbeck, Merck, Novartis, Organon, Pfizer, Sanofi, Tecnifar and TEVA, and is a current board member of the European Headache Federation and of Lifting The Burden. PRH has received grants from Amgen, Eli Lilly, Kallyope and Bristol Myers Squibb, and honoraria and travel expenses in relation to educational duties from Allergan, Novartis, Teva, Pfizer and Almirall, and is a current board member of the European Headache Federation. AKH is a member of the Editorial Board of The Journal of Headache and Pain and a board member of Lifting The Burden. MP has received consultancy fees from Abbvie, and is co-founder and president of MiGRA Portugal \u2013 the Portuguese Migraine and Headache Patients\u2019 Association. UR declares institutional fees to Universit\u00e4tsmedizin Greifswald and Charit\u00e9 Universit\u00e4tsmedizin Berlin, participation in advisory boards of Eli Lilly, AbbVie, Lundbeck, Eli Lilly, Novartis, Pfizer and Teva; consultations or scientific presentations for AbbVie, Lundbeck, Eli Lilly, Novartis, Medscape, Pfizer and Teva, has received research grants from Novartis Pharma (CHERUB 01), and is a current board member of the European Headache Federation. KR has received honoraria for contributions to advisory boards or oral presentations from Novartis, Teva, Lundbeck, AbbVie, Pfizer, Viatris and Berlin Chemie, and is a current board member of the European Headache Federation. MSdR has received consulting fees and honoraria for lectures and\/or presentations from Eli Lily, Lundbeck, Novartis, Organon and Teva, has participated in clinical trials as the principal investigator for Lundbeck, and is second vice president of the European Headache Federation. HWS has received consultant fees from Lundbeck, Pfizer, Abbvie, Lilly and Novartis, and is chairman of the Education Committee of the International Headache Society. ET is a current board member of the European Headache Federation. JV has received personal fees and nonfinancial support from Pfizer, Lilly and Teva, personal fees from Novartis and Lundbeck, and grants and nonfinancial support from Allergan\/AbbVie, and is a current board member of the European Headache Federation. TJS is associate editor of The Journal of Headache and Pain and a board member of Lifting The Burden. No author declares competing interests relevant to this statement.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"100"}}